Form 4: Camp4 Director & 10% Owner Plans Future Stock Acquisition

A director and 10% owner of Camp4 Therapeutics Corp, Amir Nashat, is scheduled to acquire common stock through affiliated entities in a private placement on September 11, 2025.

Summary

• Amir Nashat, a Director and 10% Owner of Camp4 Therapeutics Corp, reported transactions involving the acquisition of common stock.
• These transactions are scheduled to occur on September 11, 2025, as part of a private placement.
• Polaris Partners VII, L.P. (PP VII) is scheduled to acquire 1,221,721 shares of Common Stock at $1.53 per share.
• Polaris Entrepreneurs' Fund VII, L.P. (PEF VII) is scheduled to acquire 85,468 shares of Common Stock at $1.53 per share.
• These acquisitions are pursuant to a Securities Purchase Agreement dated September 9, 2025.
• Following these scheduled transactions, PP VII will beneficially own 2,825,500 shares, PEF VII will beneficially own 197,661 shares, and Polaris Partners X, L.P. (PP X) beneficially owns 909,090 shares (no new transaction reported for PP X in this filing).
• Amir Nashat, through his roles in Polaris Management Co. VII, L.L.C. and Polaris Partners GP X, L.L.C., may be deemed to have shared voting, investment, and dispositive power over these securities but disclaims beneficial ownership except for pecuniary interests.

Sentiment

Score: 7

Explanation: The planned acquisition by a director and 10% owner in a private placement indicates confidence and provides future capital, which is generally positive. The future date of the transaction is unusual for a Form 4 but is explained by a pre-arranged plan.

Positives

• A director and significant shareholder (10% owner) is increasing their stake in the company, which can signal confidence in future prospects.
• The private placement is expected to provide capital to the issuer, Camp4 Therapeutics Corp, on the scheduled transaction date.

Negatives

• The reported transaction date of September 11, 2025, is in the future, meaning the capital infusion and ownership change have not yet occurred, introducing a time lag.

Risks

• Future market conditions between the filing date and September 11, 2025, could impact the value of the acquired shares.
• The reporting person disclaims beneficial ownership except to the extent of their pecuniary interests, which is standard but highlights the indirect nature of the ownership and potential for differing interests among the managing members of the investment entities.

Future Outlook

The filing indicates a planned future capital infusion into Camp4 Therapeutics Corp through a private placement, suggesting a strategic move by the company and its investors to secure funding and potentially advance its objectives.

Industry Context

Private placements are a common financing mechanism in the biotechnology and pharmaceutical sectors, often used by companies to fund research and development, clinical trials, or general corporate purposes. The participation of a director and 10% owner in such a placement suggests continued investor confidence in the company's long-term potential within the competitive biotech landscape.

Comparison to Industry Standards

• Insider buying, particularly by a director and significant owner, is generally viewed positively across industries as it aligns management/investor interests with shareholders.
• Private placements are a standard method for companies, especially in R&D-intensive industries like biotech, to raise capital without the extensive process of a public offering. The purchase price of $1.53 per share would need to be compared to the prevailing market price of CAMP stock around the September 2025 date to assess if it represents a premium or discount relative to market value, which is not provided in this filing.

Related Party Transactions

• The scheduled acquisition of shares by entities affiliated with Director Amir Nashat (Polaris Partners VII, L.P. and Polaris Entrepreneurs' Fund VII, L.P.) constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The private placement is expected to bring in capital, which can be beneficial for the company's operations, and signals insider confidence. However, if new shares are issued, it could lead to dilution.
• Company: Will receive capital from the private placement, which can be used for operations, research and development, or other strategic initiatives.

Next Steps

• The private placement transaction is scheduled to occur on September 11, 2025.

Key Dates

Recommendation

While the planned insider buying by a director and 10% owner in a private placement signals confidence and provides future capital, the transaction is scheduled for a future date (September 11, 2025). Without current market context or further details on the company's financial performance or strategic developments leading up to this future date, a 'hold' recommendation is prudent. Investors should monitor the company's progress and the actual execution of this transaction.

Keywords

Camp4 Therapeutics, CAMP, Amir Nashat, Insider Buying, Private Placement, SEC Form 4, Director Purchase, 10% Owner, Biotechnology, Equity Acquisition, Rule 10b5-1